Revolution Medicines Doubles Stock Offering Target to $2 Billion Following Pancreatic Cancer Breakthrough [TheStreet.com]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: TheStreet.com
Following this clinical success, the California biotech doubled its fundraising target, aiming for a $2 billion stock and debt offering to draw in new investors. On Monday, mere hours after revealing the late-stage trial results, Revolution announced an initial $1 billion stock offering. By Wednesday, the company aggressively upgraded that goal. They now plan to sell more than 10.5 million shares of common stock to hit the new $2 billion mark. Revolution priced this latest raise at $142 per share. While this sits slightly below the recent closing price of $152.54, it marks a massive jump from the company's previous valuation. Before releasing the trial data, shares hovered around $96. The positive clinical readout immediately sparked a 40% rally. The late-stage RASolute 302 study drove this financial surge. Revolution's RAS blocker, daraxonrasib, more than doubled patient survival rates. Patients taking the experimental drug achieved an overall survival of 13.2 months. In contra
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Why Revolution Medicines (RVMD) Still Looks Like a Prime Takeover Target After Daraxonrasib Data [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines prices $2B in concurrent stock, notes offerings [Seeking Alpha]Seeking Alpha
- Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior NotesGlobeNewswire
RVMD
Earnings
- 2/25/26 - Miss
RVMD
Sec Filings
- 4/17/26 - Form 4
- 4/17/26 - Form 8-K
- 4/16/26 - Form 8-K
- RVMD's page on the SEC website